Notícias Artelo Biosciences Inc - ARTL | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Artelo Biosciences Inc (ARTL)
Artelo Biosciences Inc (ARTL) Notícias

Artelo Biosciences Inc (ARTL)

1,39

0,02

(1,46%)

Fechado 13 Fevereiro 6:00PM

Atrasado por 15 minutos

1,39

0,00

( 0,00% )

Pré-mercado: 7:23AM

Atrasado por 15 minutos

Ferramentas de nível profissional para investidores individuais.

Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium

Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society

Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24

Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update

Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th

Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time

Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge

Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12

Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany

Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

1
2
Próxima

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Artelo Biosciences

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições